PMID- 25789798
OWN - NLM
STAT- MEDLINE
DCOM- 20150615
LR  - 20181202
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 14
IP  - 5
DP  - 2015 May
TI  - Combination therapy for patients with uncontrolled type 2 diabetes mellitus: 
      adding empagliflozin to pioglitazone or pioglitazone plus metformin.
PG  - 789-93
LID - 10.1517/14740338.2015.1020294 [doi]
AB  - INTRODUCTION: For patients with type 2 diabetes mellitus (T2DM), there is a 
      growing interest in sodium glucose co-transporter 2 (SGLT2) inhibitors, a class 
      of glucose-lowering agents that act independently of insulin secretion and 
      insulin action and also have a weight-lowering effect. Empagliflozin is an SGLT2 
      inhibitor that has been demonstrated to significantly reduce blood glucose levels 
      and is well tolerated in patients with T2DM. AREAS COVERED: Kovacs et al. have 
      reported a randomized, placebo-controlled study of empagliflozin as add-on to 
      pioglitazone or pioglitazone plus metformin in patients with T2DM. The study 
      results are evaluated, and potential impact on clinical practice is considered. 
      EXPERT OPINION: The addition of empagliflozin to pioglitazone or pioglitazone 
      plus metformin treatment may offer some advantages. Together, their complementary 
      mechanisms of action result in significant reductions in glycated hemoglobin 
      levels, weight, and blood pressure, with a low risk of hypoglycemia, but were 
      associated with an increased risk of events consistent with genital mycotic 
      infections.
FAU - Blevins, Thomas
AU  - Blevins T
AD  - Texas Diabetes & Endocrinology, P.A , 6500 N MoPac Expwy, Building III, Suite 
      200, Austin, TX 78731 , USA +1 512 458 8400 ; TBlevins@texasdiabetes.com.
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150319
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiazolidinediones)
RN  - 9100L32L2N (Metformin)
SB  - IM
CON - Diabetes Obes Metab. 2014 Feb;16(2):147-58. PMID: 23906415
MH  - Benzhydryl Compounds/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glucosides/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Metformin/*therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Thiazolidinediones/*therapeutic use
MH  - Weight Loss/*drug effects
OTO - NOTNLM
OT  - Phase III clinical trial
OT  - SGLT2 inhibitors
OT  - combination therapy
OT  - empagliflozin
OT  - metformin
OT  - pioglitazone
OT  - type 2 diabetes mellitus
EDAT- 2015/03/20 06:00
MHDA- 2015/06/16 06:00
CRDT- 2015/03/20 06:00
PHST- 2015/03/20 06:00 [entrez]
PHST- 2015/03/20 06:00 [pubmed]
PHST- 2015/06/16 06:00 [medline]
AID - 10.1517/14740338.2015.1020294 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2015 May;14(5):789-93. doi: 10.1517/14740338.2015.1020294. 
      Epub 2015 Mar 19.